Crescita Therapeutics Inc. (TSX:CTX)
Canada
· Delayed Price · Currency is CAD 0.750
0.00 (0.00%)
Apr 28, 2026, 1:49 PM EST
Crescita Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 21.12 | 19.58 | 17.52 | 23.53 | 16.77 | Upgrade
|
| Revenue Growth (YoY) | 7.85% | 11.74% | -25.52% | 40.29% | 7.22% | Upgrade
|
| Cost of Revenue | 10.01 | 10.59 | 7.16 | 10.34 | 6.76 | Upgrade
|
| Gross Profit | 11.11 | 8.99 | 10.36 | 13.18 | 10.01 | Upgrade
|
| Selling, General & Admin | 10.82 | 10.81 | 10.12 | 10.57 | 9.5 | Upgrade
|
| Research & Development | 0.57 | 0.65 | 0.7 | 0.61 | 0.63 | Upgrade
|
| Operating Expenses | 12.13 | 12.21 | 12.32 | 12.65 | 11.51 | Upgrade
|
| Operating Income | -1.02 | -3.22 | -1.96 | 0.53 | -1.5 | Upgrade
|
| Interest Expense | -0.04 | -0.07 | -0.09 | -0.16 | -0.24 | Upgrade
|
| Interest & Investment Income | 0.33 | 0.5 | 0.51 | 0.26 | 0.18 | Upgrade
|
| Earnings From Equity Investments | -0.03 | -0.05 | 0.02 | -0.06 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.16 | -0.04 | 0.01 | -0.05 | -0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.47 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 0.86 | -2.87 | -1.51 | 0.52 | -1.79 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.28 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.67 | 0.11 | -0.02 | -0.12 | 0.78 | Upgrade
|
| Pretax Income | -0.08 | -2.76 | -1.53 | 0.4 | -1.01 | Upgrade
|
| Income Tax Expense | 0.01 | -0.01 | 0.46 | -0.46 | 0.1 | Upgrade
|
| Earnings From Continuing Operations | -0.09 | -2.75 | -1.99 | 0.86 | -1.11 | Upgrade
|
| Net Income | -0.09 | -2.75 | -1.99 | 0.86 | -1.11 | Upgrade
|
| Net Income to Common | -0.09 | -2.75 | -1.99 | 0.86 | -1.11 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 20 | 21 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 20 | 21 | 21 | Upgrade
|
| Shares Change (YoY) | -2.61% | -4.44% | -3.55% | 1.18% | -1.02% | Upgrade
|
| EPS (Basic) | -0.00 | -0.14 | -0.10 | 0.04 | -0.05 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.14 | -0.10 | 0.04 | -0.05 | Upgrade
|
| Free Cash Flow | -0.04 | 0.63 | 1.94 | -1.25 | -1.94 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | 0.03 | 0.10 | -0.06 | -0.09 | Upgrade
|
| Gross Margin | 52.60% | 45.91% | 59.15% | 56.03% | 59.72% | Upgrade
|
| Operating Margin | -4.84% | -16.42% | -11.16% | 2.25% | -8.92% | Upgrade
|
| Profit Margin | -0.44% | -14.04% | -11.33% | 3.66% | -6.59% | Upgrade
|
| Free Cash Flow Margin | -0.17% | 3.21% | 11.09% | -5.31% | -11.59% | Upgrade
|
| EBITDA | 0.04 | -2.27 | -0.86 | 1.61 | -0.48 | Upgrade
|
| EBITDA Margin | 0.21% | -11.61% | -4.89% | 6.86% | -2.86% | Upgrade
|
| D&A For EBITDA | 1.07 | 0.94 | 1.1 | 1.08 | 1.02 | Upgrade
|
| EBIT | -1.02 | -3.22 | -1.96 | 0.53 | -1.5 | Upgrade
|
| EBIT Margin | -4.84% | -16.42% | -11.16% | 2.25% | -8.92% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.